PARP抑制剂及基因检测在转移性去势抵抗性前列腺癌中的研究进展  

Research progress of PARP inhibitors and gene test in metastatic castration-resistant prostate cancer

作　　者：项方政 苏文惠 张宇兵 郑伏甫[1] XIANG Fangzheng;SU Wenhui;ZHANG Yubing;ZHENG Fufu(Department of Urology,the First Affiliated Hospital,Sun Yat-sen University,Guangdong Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院泌尿外科,广东广州510080

出　　处：《现代肿瘤医学》2024年第23期4539-4547,共9页Journal of Modern Oncology

摘　　要：转移性去势抵抗性前列腺癌(metastatic castration-resistant prostate cancer,mCRPC)严重威胁晚期前列腺癌患者的生活质量和生存时间。多聚腺苷二磷酸核糖聚合酶(poly ADP-ribose polymerase,PARP)抑制剂作为靶向治疗的代表药物,对DNA损伤修复相关基因突变的mCRPC患者有显著的治疗疗效。随着对PARP抑制剂作用机制和基因突变状态全面而深入的研究,mCRPC的精准诊疗方案不断得到改良与补充,以期为患者带来最佳生存获益和最轻不良反应。该文对近年来mCRPC阶段的患者使用PARP抑制剂单药治疗、联合治疗以及基因检测的研究进展进行综述,讨论了PARP抑制剂单药及联治的疗效、不良反应以及基因检测的指导意义,以期为临床提供参考。Metastatic castration-resistant prostate cancer(mCRPC)seriously threatens the living quality and survival time of patients with advanced prostate cancer.As the representative of targeted therapy,poly ADP-ribose polymerase(PARP)inhibitors have shown superior efficacy in mCRPC patients with mutations in DNA damage repair related genes in multiple studies.With the comprehensive and in-depth study of the therapeutic mechanisms of PARP inhibitors and the mutation states of genes,the precise program of diagnosis and treatment in mCRPC has been constantly improved and supplemented,hoping to offer the best survival benefit and the mildest adverse reaction to the patients.This review summarizes the research progress of PARP inhibitors monotherapy,combination therapy and gene test in mCRPC in recent years.It discusses the therapeutic efficacy and adverse reactions of PARP inhibitors monotherapy and combination therapy and the guiding significance of gene test,in order to provide clinical reference.

关 键 词：转移性去势抵抗性前列腺癌 多聚腺苷二磷酸核糖聚合酶抑制剂 基因检测 研究进展 

分 类 号：R737.25[医药卫生—肿瘤]